Description
-
Randomised, double-blind, placebo controlled study
-
4 injections per dosing visit
-
Dosing visits every 4 weeks
Trial length
32 weeks of treatment and 20 week follow-up
Participant age
Participants must be ages 18+
Patient eligibility
-
Participants must have a diagnosis of atopic dermatitis at least 6 months prior to starting the study
-
Participants must have an inadequate response to treatments with standard of care treatments consistent with atopic dermatitis treatment guidelines for at least 4 consecutive weeks
-
Participants must NOT have had recent exposure to live or attenuated vaccines within 2 weeks of the screening.
-
Participants must NOT have human immunodeficiency virus (HIV) infection, or infection with hepatitis B or hepatitis C viruses.
-
Female participants must NOT be pregnant
-
Female participants must NOT be breastfeeding
-
Participants must meet one of the following criteria associated with anti-inflammatory protein therapeutics to treat atopic dermatitis
-
Partial responders or non-responders to anti-inflammatory protein therapeutics with ≥12 weeks of treatment
-
Participants with intolerance or adverse reaction to anti-inflammatory protein therapeutics
-
Participants with loss of access to anti-inflammatory protein therapeutics.
-
-
BMI of 17.5 to 40 kg/m2; and a total body weight >45 kg
13 onsite visits
*Travel is reimbursed for each visit
** Please contact site for further information regarding eligibility
Study Requirements
Objectives
To investigate the efficacy of the medication PF-07275315 in adult participants with moderate-severe atopic dermatitis
Description
-
Randomised, double-blind, placebo controlled study
-
4 injections per dosing visit
-
Dosing visits every 4 weeks
Trial length
32 weeks of treatment and 20 week
follow-up
Participant age
Participants must be ages 18+
Patient eligibility
-
Participants must have a diagnosis of atopic dermatitis at least 6 months prior to starting the study
-
Participants must have an inadequate response to treatments with standard of care treatments consistent with atopic dermatitis treatment guidelines for at least 4 consecutive weeks
-
Participants must NOT have had recent exposure to live or attenuated vaccines within 2 weeks of the screening.
-
Participants must NOT have human immunodeficiency virus (HIV) infection, or infection with hepatitis B or hepatitis C viruses.
-
Female participants must NOT be pregnant
-
Female participants must NOT be breastfeeding
-
Participants must meet one of the following criteria associated with anti-inflammatory protein therapeutics to treat atopic dermatitis
-
Partial responders or non-responders to anti-inflammatory protein therapeutics with ≥12 weeks of treatment
-
Participants with intolerance or adverse reaction to anti-inflammatory protein therapeutics
-
Participants with loss of access to anti-inflammatory protein therapeutics.
-
-
BMI of 17.5 to 40 kg/m2; and a total body weight >45 kg
13 onsite visits
*Travel is reimbursed for each visit
Study Requirements
Objectives
To investigate the efficacy of the medication PF-07275315 in adult participants with moderate-severe atopic dermatitis
Get in touch with us
Our friendly team would love to hear from you!